Could Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.

NMRA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: N/A

Insider Buying (Last 12 Months): $61,619,186.74

Insider Selling (Last 12 Months): $0.00

Neumora Therapeutics Insider Trading History Chart

Neumora Therapeutics Share Price & Price History

^$9.35

▲ +0.13 (1.41%)

As of 05/3/2024 02:52 PM ET

Days: 30 | 90 | 365

Forget Bitcoin: This $8 Stock Is the Next Big Thing

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

Neumora Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/14/2023	Arch Venture Partners Xii, Llc	Major Shareholder	Buy	3,357	$11.98	$40,216.86	4,131,207
11/13/2023	Kristina Burow	Director	Buy	31,653	$11.75	$371,922.75	4,127,850
11/10/2023	Kristina Burow	Director	Buy	17,275	$11.49	$198,489.75	4,096,197
11/9/2023	Arch Venture Partners Xii, Llc	Major Shareholder	Buy	31,079	$10.53	$327,261.87	4,078,922
11/8/2023	Kristina Burow	Director	Buy	92,251	$11.03	$1,017,528.53	4,047,843
11/7/2023	Arch Venture Partners Xii, Llc	Major Shareholder	Buy	30,192	$11.50	$347,208.00	3,955,592
11/6/2023	Kristina Burow	Director	Buy	43,082	$11.55	$497,597.10	3,925,400
11/3/2023	Kristina Burow	Director	Buy	22,420	$11.38	$255,139.60	3,882,318
9/29/2023	Arch Venture Partners Xii, Llc	Major Shareholder	Buy	34,560	$13.98	$483,148.80	3,859,898
9/28/2023	Kristina Burow	Director	Buy	41,951	$13.44	$563,821.44	3,825,338
9/27/2023	Arch Venture Partners Xii, Llc	Major Shareholder	Buy	24,504	$12.31	$301,644.24	3,783,387
9/26/2023	Kristina Burow	Director	Buy	34,000	$11.73	$398,820.00	3,758,883
9/25/2023	Arch Venture Partners Xii, Llc	Major Shareholder	Buy	60,740	$11.22	$681,502.80	3,724,883
9/22/2023	Arch Venture Partners Xii, Llc	Major Shareholder	Buy	40,000	$11.14	$445,600.00	3,664,143
9/19/2023	Amgen Inc	Major Shareholder	Buy	1,764,705	$17.00	$29,999,985.00	35,368,653
9/19/2023	Henry O Gosebruch	CEO	Buy	15,000	$12.62	$189,300.00	15,000
9/19/2023	Kristina Burow	Director	Buy	1,500,000	$17.00	$25,500,000.00	3,624,143

Forget Bitcoin: This $8 Stock Is the Next Big Thing

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

SEC Filings (Institutional Ownership Changes) for Neumora Therapeutics (NASDAQ:NMRA)

47.65% of Neumora Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Neumora Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/1/2024	Auour Investments LLC	105,087	$1.45M	0.5%	N/A	0.066%
4/23/2024	Addis & Hill Inc	314,821	$4.19M	3.6%	N/A	0.198%
4/22/2024	Windmill Hill Asset Management Ltd	26,121	$0.36M	0.1%	N/A	0.016%
2/14/2024	Avidity Partners Management LP	1,990,632	$33.94M	1.2%	+10.6%	1.304%
2/13/2024	Tower Research Capital LLC TRC	2,558	$44K	0.0%	N/A	0.002%
2/6/2024	Amalgamated Bank	1,709	$29K	0.0%	N/A	0.001%
2/1/2024	New York State Common Retirement Fund	6,900	$0.12M	0.0%	N/A	0.005%
1/30/2024	Strs Ohio	3,200	$54K	0.0%	N/A	0.002%
1/12/2024	SG Americas Securities LLC	6,308	$0.11M	0.0%	N/A	0.004%
12/6/2023	Citigroup Inc.	14,416	$0.20M	0.0%	N/A	0.009%
11/15/2023	Laurion Capital Management LP	21,557	$0.30M	0.0%	N/A	0.014%
11/14/2023	Soros Fund Management LLC	10,000	$0.14M	0.0%	N/A	0.007%
11/14/2023	Avidity Partners Management LP	1,800,000	$25.40M	1.0%	N/A	1.179%
11/13/2023	FMR LLC	5,624,353	$79.36M	0.0%	N/A	3.683%
11/9/2023	Johnson & Johnson	912,128	$12.87M	4.7%	N/A	0.597%
10/23/2023	WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST	3,309,124	$46.69M	0.6%	N/A	2.178%

Data available starting January 2016

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $9.35

$9.21

$9.66

50 Day Range

MA: $13.88

$9.06

$19.28

52 Week Range

Now: $9.35

$8.82

$21.00

Volume

205,781 shs

Average Volume

479,913 shs

Market Capitalization

$1.49 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Neumora Therapeutics?: Neumora Therapeutics' top insider shareholders include:
Amgen Inc (Major Shareholder)
Arch Venture Partners Xii, Llc (Major Shareholder)
Kristina Burow (Director)
Henry O Gosebruch (CEO)
Learn More about top insider investors at Neumora Therapeutics.
Who are the major institutional investors of Neumora Therapeutics?: Neumora Therapeutics' top institutional investors include:
Addis & Hill Inc — 0.20%
Auour Investments LLC — 0.07%
Windmill Hill Asset Management Ltd — 0.02%
Learn More about top institutional investors of Neumora Therapeutics stock.
Which institutional investors are buying Neumora Therapeutics stock?: Within the previous quarter, NMRA stock was acquired by institutional investors including:
Addis & Hill Inc
Auour Investments LLC
Windmill Hill Asset Management Ltd
In the last year, these company insiders have bought Neumora Therapeutics stock:
Amgen Inc (Major Shareholder)
Arch Venture Partners Xii, Llc (Major Shareholder)
Kristina Burow (Director)
Henry O Gosebruch (CEO)
Learn More investors buying Neumora Therapeutics stock.

Urgent Nvidia Warning

From Altimetry | Ad

Click here to access…